NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeoGenomics reports robust Q4 earnings, targets profitability in 2023

NeoGenomics delivered strong financial performance in Q4 2022 and full-year 2022, with a focus on sustainable long-term growth. The company aims to achieve adjusted EBITDA positive by Q4 2023 through strategic initiatives, including revenue growth, margin improvement, and operational efficiencies.

NeoGenomics reports robust Q1 results, eyes growth in diagnostics

NeoGenomics' Q1 performance reflects strong revenue growth and operational improvements, driven by strategic priorities and salesforce optimization.
While facing challenges in market share capture and modalities impact, the company's focus on automation and revenue cycle management presents growth opportunities.
Overall, NeoGenomics is well-positioned to achieve its full-year guidance and capitalize on opportunities in advanced diagnostics and revenue optimization.

NeoGenomics excels in Q2, raises guidance on strong growth prospects

NeoGenomics delivered strong financial results, raised revenue guidance, and improved operational efficiencies. With a focus on NGS portfolio expansion, revenue growth, and strategic planning, the company is well-positioned for future success amidst market challenges.

NeoGenomics reports strong Q3 growth, eyes accelerated breast coverage

NeoGenomics demonstrated robust growth and operational improvements in Q3.
The company's focus on high-value areas like breast cancer is a strategic advantage.
Challenges include potential delays in submissions and ongoing labor inflation concerns.
Opportunities lie in accelerated breast coverage, sales force expansion, and payment efficiency enhancements.

NeoGenomics reports strong Q4 earnings and outlines growth strategies

NeoGenomics delivered strong financial performance in Q4 2023, with revenue growth, improved profitability, and a focus on strategic investments for future growth and operational efficiency.
The company's strengths lie in its strategic focus areas, commitment to value creation, and solid financial position, positioning it well for sustainable success and market leadership.
While facing challenges such as market dynamics and operational hurdles, NeoGenomics has opportunities in expanding market share, product innovation, and strategic partnerships to drive growth and profitability.
Overall, NeoGenomics' performance, strengths, challenges, and opportunities indicate a resilient business poised for continued growth, profitability, and market expansion in the evolving healthcare landscape.

NeoGenomics reports robust Q1 growth, eyes M&A and innovation

NeoGenomics delivered strong financial performance in Q1 2024, driven by revenue growth and operational improvements.
The company's strategic priorities, leadership enhancements, and regulatory outlook bode well for future growth and innovation.
While facing challenges in legal defense and market dynamics, NeoGenomics is well-positioned to leverage opportunities in M&A, product launches, and commercial expansion.

NeoGenomics reports robust Q2 growth amidst legal challenges

NeoGenomics delivered strong financial performance in Q2 2024, with revenue growth, positive adjusted EBITDA, and raised revenue guidance for the year.
The company's strategic focus on innovation, operational efficiency, and growth positions it well to capitalize on the evolving healthcare landscape and increasing demand for advanced diagnostics.
While facing legal challenges, NeoGenomics is actively exploring solutions and remains committed to driving value creation and expanding its market presence through product development and strategic initiatives.

NeoGenomics reports record Q3 earnings, eyes growth through innovation

NeoGenomics delivered strong financial performance in Q3 2024, with record revenues and improved adjusted EBITDA, driven by NGS growth.
The company's strategic focus on sustainable growth, innovation, and financial management strengths position it well for future success.
Challenges lie in addressing profitability evolution, successful Neo Helix integration, and balancing short-term impact with long-term value creation.
Opportunities include Neo Helix development, revenue mix diversification, and achieving the revised adjusted EBITDA guidance range.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of NeoGenomics, Inc. (NASDAQ: NEO) resulting from allegations that NeoGenomics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased NeoGenomics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrange.

ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco and will present on Monday, Jan. 8, 8:15 p.m. ET.

NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a subsidiary of NeoGenomics Inc., will appeal the preliminary injunction issued by the United States District Court for the Middle District of North Carolina. The initial determination is that Natera, Inc. demonstrated a likelihood that products using RaDaR technology infringe one Natera, Inc. patent.

NeoGenomics to Appeal Ruling

FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio Breast Cancer Symposium (SABCS). RaDaR data will be presented during a Poster Spotlight Session featuring an updated analysis of the TRACER study, which assessed patients with early-stage breast cancer across multiple subtypes and the potential utility of using RaDaR in this setting, including for baseline detection, for monitoring therapy response in the neoadjuvant setting, and for post-operative recurrence monitoring.

NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response

FT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New York City. Members of NeoGenomics' management team will participate in a fireside chat on Wednesday, November 29th at 9:00 a.m.

NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 28.2% in NeoGenomics (NEO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High?

Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, NeoGenomics (NEO) Q3 Earnings: A Look at Key Metrics

NeoGenomics, Inc (NASDAQ:NEO ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 AM ET Company Participants Kendra Sweeney - VP, IR Chris Smith - CEO Jeff Sherman - CFO Vishal Sikri - President, Advanced Diagnostics Warren Stone - President, Clinical Services Conference Call Participants Vidyun Bais - BTIG Andrew Brackman - William Blair Alex Nowak - Craig-Hallum Capital Group David Westenberg - Piper Sandler Madison Pasterchick - Morgan Stanley Joseph Stringer - Needham & Company Tom Stevens - TD Cowen Prashant Kota - Goldman Sachs Jacob Krahenbuhl - Stephens Puneet Souda - Leerink Partners Operator Greetings. Welcome to the NeoGenomics Third Quarter 2023 Earnings Call -- Third Quarter 2023 Financial Results Conference Call and Webcast.

NeoGenomics, Inc (NEO) Q3 2023 Earnings Call Transcript

Third Quarter Revenue Increased 18% to $152 Million FORT MYERS, FL / ACCESSWIRE / November 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2023 as compared to September 30, 2022. Third Quarter 2023 Highlights Q3 2023 Results Consolidated revenue increased 18% to $152 million Clinical Services revenue increased 20% to $128 million Advanced Diagnostics revenue increased 8% to $24 million Net loss decreased 50% to $19 million Adjusted EBITDA increased 129% to positive $3 million Raised Full-Year 2023 Guidance Raised revenue guidance to a range of $585 million - $592 million, representing 15% - 16% year-over-year growth Raised Adjusted EBITDA guidance to a range of $4 million loss - $1 million loss, representing a 92% - 98% year-over-year increase "We had another strong quarter in which we delivered significant revenue growth over prior year, continued to gain operating leverage as we achieved positive adjusted EBITDA, and improved turnaround time for our customers for the fourth consecutive quarter," said Chris Smith, Chief Executive Officer of NeoGenomics.

NeoGenomics Reports Third Quarter 2023 Results

NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?

The consensus price target hints at a 35.1% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think NeoGenomics (NEO) Could Surge 35.08%: Read This Before Placing a Bet

Neo Comprehensive™ - Heme Cancers is a large and comprehensive next-generation sequencing panel with broad coverage of genes associated with blood cancers Early-stage NSCLC Panel - a therapy selection panel providing a comprehensive overview of biomarkers for detecting early-stage lung cancer FT. MYERS, FL / ACCESSWIRE / October 24, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today the commercial availability of two new tests, expanding its cancer portfolio of innovative products.

NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics (NEO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock?

FT. MYERS, FL / ACCESSWIRE / October 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its third quarter 2023 financial results on Monday, November 6, 2023. Company management will host a webcast and conference call that day at 4:30 p.m.

NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023

NeoGenomics (NEO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NeoGenomics (NEO) Upgraded to Strong Buy: What Does It Mean for the Stock?

NeoGenomics, Inc (NASDAQ:NEO ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations Chris Smith - Chief Executive Officer Jeff Sherman - Chief Financial Officer Vishal Sikri - President, Advanced Diagnostics Warren Stone - President, Clinical Services Melody Harris - President, Enterprise Operations Conference Call Participants Dan Brennan - TD Cowen Alex Nowak - Craig-Hallum Capital Group David Delahunt - Goldman Sachs Mark Massaro - BTIG Tejas Savant - Morgan Stanley Derik De Bruin - Bank of America Mike Matson - Needham & Company Mason Carrico - Stephens Andrew Cooper - Raymond James Operator Welcome to the NeoGenomics Second Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.

NeoGenomics, Inc (NEO) Q2 2023 Earnings Call Transcript

Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

NeoGenomics (NEO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Second Quarter Revenue Increased 18% to $147 Million FORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2023 as compared to June 30, 2022. Highlights Consolidated revenue increased 18% to $147 million Clinical Services revenue increased 17% to $123 million Advanced Diagnostics revenue increased 22% to $24 million Net loss decreased 31% to $24 million Adjusted EBITDA increased 87% to negative $2 million "Our team delivered another excellent quarter with double-digit growth in both our Clinical Services and Advanced Diagnostics businesses," said Chris Smith, Chief Executive Officer of NeoGenomics.

NeoGenomics Reports Second Quarter 2023 Results

FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR® assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection. Following this decision, effective as of March 24, 2023, the RaDaR assay is now covered for fee-for-service Medicare patients within the United States with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

Tesla

Allegiant Travel Company

Arlo Technologies Inc

eXp World Holdings Inc

PROG Holdings

B. Riley Financial

Sotera Health

World Acceptance

What's been one of the easiest ways to make big money on stocks this year? Pick up stocks in and out of the S&P 500 others left for dead.

Investors Make A Bundle On 10 Stocks Others Panic Sold (Like Tesla)

FT. MYERS, FL / ACCESSWIRE / July 18, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023. Company management will host a webcast and conference call that day at 8:30 a.m.

NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023

PRESS RELEASE - INSIDE INFORMATION/ REGULATED INFORMATION 18 July 202 3 , 7:00 AM CE S T

Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery

FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors. The Board has elected three new independent board members to join the board effective June 29, 2023.

NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

FT. MYERS, FL / ACCESSWIRE / June 15, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that its RaDaR® assay, a personalized liquid biopsy for minimal/molecular residual disease (MRD) and recurrence detection, has obtained its first pan-cancer commercial coverage by Blue Shield of California. Effective August 1, 2023, Blue Shield of California has agreed to provide commercial coverage of RaDaR across all indications for plan members, representing approximately 4.7 million covered lives.

NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Data from a retrospective analysis of the Phase 3 PENELOPE-B study was presented in part at the 2023 ASCO® Annual Meeting on Friday, June 2nd in Chicago, IL.

News for NeoGenomics Stock (NEO)